Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Hematologic Disorders : Relapsed or refractory hematologic malignancies
This study is done for leukemia or lymphoma that has relapsed (come back) or is refractory (unresponsive) and strong chemotherapy (anti-cancer drugs) (called re-induction treatment) is needed. Re-induction treatment is given in an attempt to bring the disease back into remission (no signs or symptoms of leukemia or lymphoma).
There is no “standard” therapy for recurrent leukemia or lymphoma. Most commonly used treatment plans have drugs similar to those used in this protocol, although the drugs may be given in different combinations and on different schedules.
Researchers want to know if adding a new drug, called Bendamustine will be safe and possible to give with other re-induction chemotherapy drugs.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Sima Jeha, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Referring or consulting physicians only: firstname.lastname@example.org
For all other inquiries about St. Jude Children's Research Hospital studies: email@example.com
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.